School of Pharmacy
The University of Mississippi

Dr. Hoang V. Le

Posted on: August 29th, 2016 by trippsop
Assistant Professor of Medicinal Chemistry
Faser Hall 419


  • Ph.D. Cornell University
  • B.S. University of California, Berkeley


  • Assistant Professor of Medicinal Chemistry
  • Research Assistant Professor in the Research Institute of Pharmaceutical Sciences

Career Highlights:

Hoang V. Le graduated from the University of California, Berkeley with a B.S. degree in chemistry in 2008. While at Berkeley, Hoang worked in the laboratory of Professor Kenneth Raymond, studying supramolecular chemistry, synthesizing dicationic linkers, and investigating their stability in supramolecular systems. In 2013, he graduated from Cornell University with a Ph.D. degree in organic chemistry under the guidance of Professor Bruce Ganem. His graduate work expanded the scope of multicomponent reaction (MCR) chemistry by improving known synthetically useful MCRs and developing new MCRs. Hoang then held a postdoctoral position in the laboratory of Professor Richard Silverman at Northwestern University. His postdoctoral research led to the discovery and development of many inhibitors of GABA aminotransferase, human ornithine aminotransferase, and Toxoplasma gondii ornithine aminotransferase. He is a co-inventor of the licensed drug OV329, currently in preclinical development at Ovid Therapeutics for the treatment of drug-resistant epilepsy and drug addiction. In July 2016, he started his independent research career as an Assistant Professor of Medicinal Chemistry in the Department of BioMolecular Sciences at the University of Mississippi School of Pharmacy. In 2018, he received a New Investigator Award from American Association of Colleges of Pharmacy.


Anticancer Research

Metabolism in normal cells vs. one in cancer cells. The figure was originally published by Erickson and Cerione.

Cancer cells have a very different metabolism from that of normal cells from which they are derived. Glycolysis, although enhanced in cancer cells, is no longer a source of biosynthetic precursors. Instead, glutaminolysis fuels the TCA cycle with glutamine-derived α-ketoglutarate. The enhanced production of α-ketoglutarate is critical to cancer cells as it provides carbons and nitrogens for the TCA cycle to produce glutathione, fatty acids, nucleotides, hexosamines, nucleotides, and many nonessential amino acids. Glutaminase and isocitrate dehydrogenase are two critical enzymes in the production of α-ketoglutarate in cancer cells. A lot of times, when one metabolic pathway in cancer cells is blocked, they shift to enhance alternative metabolic pathways to maintain the production of essential molecules. Development of inhibitors for both critical enzymes in the α-ketoglutarate production allows us to study the effects on cancer cells when one of the enzymes is inhibited, as well as when both of the enzymes are inhibited.

κ-Opioid Receptor (KOR)​ Research

Salvinorin A, one of the most potent naturally occurring opioid agonists with high selectivity and affinity for KOR

Salvinorin A, one of the most potent naturally occurring opioid agonists with high selectivity and affinity for KOR


The κ-opioid receptor (KOR) is one of four related receptors that bind opioid-like compounds in the brain and are responsible for mediating the effects of these compounds. KOR agonists have provided therapeutic potential in the treatment of pain and convulsion, and as antidotes for opioid overdose, while KOR antagonists have proven useful in drug abuse relapse, depression, and anxiety. However, the development of current KOR ligands as therapeutic agents has been hindered by their unfavorable side effects. Current KOR agonists produce dysphoria, sedation, and depression due to their low functional selectivity, while current KOR antagonists possess unusually long pharmacokinetic profiles due to their long-acting effect. We are currently aiming to solve these problems for KOR agonists and antagonists.

Antimalarial Research

Atovaquone, the only current FDA-approved inhibitor of Plasmodium falciparum cytochrome bc1 complex.

Cytochrome bc1 complex is a dimeric multisubunit electron transport protein in the inner-mitochondrial membrane and is a proven drug target in the prevention and treatment of malaria. Cytochrome bc1 complex is essential for Plasmodium falciparum as it maintains a pool of ubiquinone for the enzyme dihydroorotate dehydrogenase, which catalyzes the ubiquinone-mediated oxidation of dihydroorotate to orotate, in the pyrimidine biosynthesis pathway. The pyrimidine biosynthesis pathway is critical for the survival of P. falciparumbecause it cannot salvage pyrimidines and therefore is completely dependent on de novo pyrimidine synthesis. Inhibition of either cytochrome bc1 complex or dihydroorotate dehydrogenase has been shown to result in death of the parasite. We are currently focusing on the development of atovaquone-based and quinolone-based inhibitors of cytochrome bc1 complex. 

Search Dr. Le’s publications



5) Le, H.V.; Hossain, M.I. “Lγ-Methyleneglutamine Compounds, Methods of Forming the Same, and Methods of Use Thereof” U.S. Provisional Patent Application No. 62/873,586, filed on July 12, 2019. 

4) Le, H.V.; Kim, S-J. “Cytochrome bc1 Complex Inhibitors and Methods of Use Thereof.” U.S. Provisional Patent Application No. 62/689,598, filed on June 25, 2018.

3) Silverman, R. B.; Le, H. V.; Hawker, D. D.; McLeod, R. L. “Inactivators of Toxoplasma Gondii Ornithine Aminotransferase for Treating Toxoplasmosis and Malaria.” United States Patent US 2018/0098952, published on December 4, 2018.

2) Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. “(S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and Related Compounds as GABA Aminotransferase Inactivators for the Treatment of Epilepsy, Addiction and Hepatocellular Carcinoma.” United States Patent US 2017/0101364 A1, published on April 13, 2017. WIPO Patent WO 2017/062942 A2, published on April 13, 2017.  

​1) Silverman, R. B.; Le, H. V.; Hawker, D. D. “Tetrahydrothiophene-based GABA Aminotransferase Inactivators.” United States Patent US 2016/0264544 A1, published on September 15, 2016. WIPO Patent WO 2016/145082 A1, published on September 15, 2016. ​